Vancomycin Versus Daptomycin for the Treatment of Methicillin-resistant Staphylococcus Aureus Bacteremia Due to Isolates With High Vancomycin Minimum Inhibitory Concentrations (MICs)

This study has been terminated.
(Low patient enrollment)
Sponsor:
Collaborators:
Henry Ford Health System
Cubist Pharmaceuticals
Information provided by (Responsible Party):
Leonard B. Johnson, St. John Health System, Michigan
ClinicalTrials.gov Identifier:
NCT01287832
First received: January 31, 2011
Last updated: December 14, 2012
Last verified: December 2012
No Study Results Posted on ClinicalTrials.gov for this Study
  Study Status: This study has been terminated.
  Study Completion Date: January 2012
  Primary Completion Date: January 2012 (Final data collection date for primary outcome measure)